Exposomics & 5P medicine

In this episode, Alice Limonciel and Gary Miller discuss the synergies of exposomics and metabolomics, the next frontier in multiomics integration, and how exposomics promises to bolster all 5Ps and the future of medicine.
Gary Miller

Gary Miller, PhD

He is Professor of Environmental Health Sciences (in Molecular Pharmacology and Therapeutics) and Vice Dean for Research Strategy and Innovation at Mailman School of Public Health, Columbia University, USA

Favorite metabolite
3,4-dihydroxyphenylacetaldehyde (DOPAL)
A toxic intermediate in the metabolism of dopamine linked to the damage to dopamine neurons in Parkinson’s disease.

Papers discussed in this episode
Zhao et al. Neurology 2024 | Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease in a Population-Based Cohort

Additional resources
Learn more about the outcomes of the Banbury conference on exposome in the Science paper, including the newly unified definition of the exposome.
Read the Washington Declaration established and signed at the Exposome Moonshot forum in May 2025, a few days after recording the episode. Follow the progress of the Exposome Moonshot.

Sign up for The Metabolomist mailing list to be the first to hear about the latest episodes and news around metabolomics at https://themetabolomist.com

Finally available – Alice’s first book
The STORY principle – A guide to the biological interpretation of metabolomics
Also featuring some of the Metabolomists from Season 1
Available on Amazon and the biocrates webshop

DE_Apple_Podcasts_Listen_Badge_RGB
spotify-podcast
Metabolomics podcast